Andrew W Hahn
Overview
Explore the profile of Andrew W Hahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hahn A, Tidwell R, Pilie P, Yu Y, Liu J, Surasi D, et al.
Prostate Cancer Prostatic Dis
. 2024 Jul;
PMID: 39019979
Background: Androgen signaling is central to prostate cancer and men's health. Prior data indicates that increasing body fat is unfavorable in the localized setting yet associated with favorable outcomes in...
12.
Lebenthal J, Kontoyiannis P, Hahn A, Lim Z, Rao P, Cheng J, et al.
Eur Urol Oncol
. 2024 Jul;
PMID: 39013742
Background And Objective: SMARCB1-deficient renal medullary carcinoma (RMC) is a rare kidney cancer associated with sickle cell hemoglobinopathies with poor outcomes described only in case reports and small series. We...
13.
Hahn A, Manyam G, Chapin B, Zhang M, Yu Y, Pettaway C, et al.
BJU Int
. 2024 Jun;
134(3):449-458.
PMID: 38837608
Objectives: To determine whether 6 months of preoperative apalutamide for intermediate-risk prostate cancer (IRPCa) reduces the aggregate postoperative radiotherapy risk and to evaluate associations of molecular perturbations with clinical outcomes...
14.
Hahn A, Koutroumpakis E, Narayan V, Aparicio A
Prostate Cancer Prostatic Dis
. 2024 May;
PMID: 38796515
No abstract available.
15.
Aparicio A, Tidwell R, Yadav S, Chen J, Zhang M, Liu J, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2751-2763.
PMID: 38683200
Purpose: To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration-resistant prostate cancers. Patients And Methods: In a modular, randomized...
16.
Crawford D, Albala D, Garnick M, Hahn A, Maroni P, McKay R, et al.
Can J Urol
. 2024 Apr;
31(2):11820-11825.
PMID: 38642459
Introduction: Risk of cardiovascular disease is higher among men with prostate cancer than men without, and prostate cancer treatments (especially those that are hormonally based) are associated with increased cardiovascular...
17.
Sherry A, Hahn A, McCaw Z, Abi Jaoude J, Kouzy R, Lin T, et al.
JAMA Netw Open
. 2024 Mar;
7(3):e243379.
PMID: 38546648
Importance: Subgroup analyses are often performed in oncology to investigate differential treatment effects and may even constitute the basis for regulatory approvals. Current understanding of the features, results, and quality...
18.
19.
Johns A, Campbell M, Gao M, Hahn A, Lim Z, Wang E, et al.
Oncologist
. 2024 Mar;
29(7):589-595.
PMID: 38478923
Background: Tivozanib has been approved as a third-line or later therapy for advanced renal cell carcinoma based on the TIVO-3 trial, which was conducted before immune checkpoint therapies (ICT), cabozantinib,...
20.
Gregg J, Magill R, Fang A, Chapin B, Davis J, Adibi M, et al.
Urol Oncol
. 2024 Jan;
42(4):116.e1-116.e7.
PMID: 38262868
Objectives: To evaluate the association of preoperative body mass index (BMI) on adverse pathology in peripheral (PZ) and transition zone (TZ) tumors at time of prostatectomy for localized prostate cancer....